Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “ACETYLSALICYLIC ACID”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,531 records · Page 85Linked to original sources
PubMedDate not supplied

[Long term prevention of thromboembolic accidents with acetylsalicylic acid in auricular fibrillation patients].

For the past few years various authors have reported the antiplatelet action and prolongation of bleeding time with the use of acetyl-salicilic acid. In the present work, we review the frequency of thromboembolism in a group of patients with rheumatic or sclerotic heart disease with atrial fibrillation, in which the treatment with coumarins was suspended and substituted for 1 gram of aspirin P.O. daily. The results were compared with a similar group studied by Cárdenas and col. During the time of the observation 10 patients had 14 thromboembolic accidents, slightly predominated by the emboli in the inferior members and in the cerebral vascular territory. The mortality was 2.5% and in 9 patients hemorrhages of little importance appeared, which could have been caused by the ASA, although it can not be proven. In comparing the results of this work with the above mentioned of Cárdenas, it appeared that the number of thromboemboli, of deaths, and secondary accidents in the group treated with ASA was less than in the group which received coumarin or which were maintained without treatment. Based on the results, it can be concluded that it is possible to substitute the coumarins with acetyl-salicilic acid in the prevention of thromboembolism, in patient with rheumatic or sclerotic heart disease with atrial fibrillation.

Adult↗
PubMed1976

[Action of acetylsalicylic acid administered by different routes on the blood and buccal tissues of rats].

Sixty female Sprague-Dawley rats, with an average weight of 120 g, have been used in this study. The experimental groups received twice a day 1 ml of a 2% acetyl-salicylic acid suspension in methyl-cellulose either per os or i.p. The control groups received methyl-cellulose without asprin. The blood was collected before any treatment and each day during the week for the purpose of counting cells. The experimental animals and their control were killed after 2, 4 and 8 days. A piece of endobuccal epithelium with its deeper tissues was cut off and frozen for histochemistry. The tissue sections were treated to show the basic enzymatic reactions of the cell. It was observed that: 1. most of the changes appear between the 4th and 8th day of the treatment: 2. depending on the administration route, certain blood cells show a peak. Microphages between the 4th and 6th day in injected animals. Lymphocytes at the same time, in the gavage group; 3. oral epithelium lesions are limited and appear lately; 4. underlying muscles are a constant target. The lesions are seen in both experimental groups as soon as the 2nd day. After a week, the lesions are more numerous. They are characterized by enzymatic inbalances with or without macrophages. The muscular cell is a real target for acetyl salicylic acid.

Administration, Oral↗
PubMed1976

[The antithrombotic treatment and prevention of recurrence with acetylsalicylic acid in myocardial infarct].

A comparison of the therapy, especially of the long-term recidivation prophylaxis of the myocardial infarction with acetyl salicylic acid and anticoagulants, on the basis of 314 observations allows of the following opinions: By means of the thrombocyte aggregation inhibitor acetyl salicylic acid an antithrombotic therapy and recidivation prophylaxis of good value can be performed. The application of acetyl salicylic acid is, concerning the course of the disease after the onset of the infarction and the frequency of recidivation, adequate to the treatment with classical anticoagulants. The practical performance of the long-term therapy with acetyl salicylic acid is significantly simplified for physician and patient compared with the application of anticoagulants. The daily dose lies uniformly at 1.5 g. There is no fear of acute haemorrhagic complications. As control only the occasional establishment of the Hb-value as well as of the time of haemorrhage is indicated. The only, however, very decisive disadvantage of the acetyl salicylic acid, the bad compatibility for the stomach, is certainly not abolished with the new drug "Micristin", but much diminished.

Animals↗